Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of Bermekimab in Healthy Chinese Participants
NCT05252520Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2023
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of bermekimab in atopic dermatitis (AD) and hidradenitis suppurativa (HS), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Serum Concentration, Time to Reach Maximum Observed Serum Concentration and 5 more. Planned start May 2023; status: withdrawn.
02
Drugs
bermekimab
03
Conditions
atopic dermatitis (AD)hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05252520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252520.